Seattle Genetics Announced Positive Results for HER2CLIMB Trial
Seattle Genetics (SGEN) announced positive topline results from the HER2CLIMB trial evaluating tucatinib in HER2-positive breast cancer. The trial compared tucatinib in combination with trastuzumab and capecitabine to trastuzumab and capecitabine
This content is for paid subscribers.
Today’s Highlights October 21, 2019